Table 1.
Clinical characteristics of patients with FSGS and MCNS
| FSGS | MCNS | P valuea | ||||||
|---|---|---|---|---|---|---|---|---|
| All | COL | TIP | CEL | PH | NOS | |||
| Case number | 43 | 5 (11.6 %) | 14 (32.6 %) | 8 (18.6 %) | 4 (9.3 %) | 12 (27.9 %) | 11 | |
| Age | 38.8 ± 2.4 | 34.0 ± 3.2 | 41.2 ± 5.0 | 36.6 ± 2.7 | 34.8 ± 5.1 | 39.4 ± 4.8 | 34.6 ± 3.8 | NS |
| Male/female | 23/20 | 2/3 | 7/7 | 4/4 | 3/1 | 7/5 | 7/4 | NS |
| Disease duration (months) | 70.8 ± 14.8 | 12.5 ± 2.5 | 8.1 ± 3.5 | 20.6 ± 6.4 | 96.0 ± 44.3 | 102.1 ± 26.0 | 1.1 ± 0.1 | <0.001 |
| Initial urinary protein (g/day) | 6.5 ± 1.0 | 6.7 ± 1.5 | 9.0 ± 2.1 | 10.3 ± 2.6 | 3.0 ± 1.4 | 2.0 ± 0.6 | 6.3 ± 0.8 | NS |
| Initial eGFR (mL/min/1.73 m2) | 53.4 ± 3.8 | 55.0 ± 16.1 | 52.6 ± 6.2 | 53.1 ± 22.8 | 54.3 ± 8.6 | 53.4 ± 8.5 | 82.5 ± 6.6 | <0.01 |
| Follow-up duration (years) | 5.3 ± 0.4 | 4.0 ± 1.1 | 6.8 ± 0.7 | 4.4 ± 0.8 | 5.5 ± 1.0 | 4.5 ± 0.8 | 4.1 ± 0.7 | NS |
| Final urinary protein (g/day) | 1.24 ± 0.29 | 1.48 ± 0.63 | 0.97 ± 0.47 | 2.08 ± 1.04 | 0.62 ± 0.08 | 1.14 ± 0.49 | 0.05 ± 0.05 | <0.001 |
| Final eGFR (mL/min/1.73 m2) | 43.1 ± 4.3 | 22.7 ± 11.8 | 50.0 ± 7.8 | 41.2 ± 28.0 | 57.3 ± 8.6 | 40.0 ± 7.9 | 84.2 ± 4.7 | <0.001 |
| △eGFR (mL/min/1.73 m2) | −11.3 ± 4.9 | −32.2 ± 10.0 | −2.8 ± 10.4 | −11.9 ± 11.6 | 3.0 ± 4.1 | −13.4 ± 5.9 | 1.7 ± 4.2 | NS |
| Remission (% of NR) | 35.7 | 100 | 21.4 | 57.1 | 0 | 41.7 | 0 | <0.05 |
| Hemodialysis (%) | 9/42 (21.4) | 3/4 (75) | 2/14 (14.3) | 2/8 (25) | 0/4 (0) | 2/12 (16.7) | 0/11 (0) | NS |
Quantitative variables are mean ± standard error
COL collapsing variant, TIP tip variant, CEL cellular variant, PH perihilar variant, NOS not otherwise specified variant, MCNS minimal change nephrotic syndrome, eGFR estimated glomerular filtration rate, △eGFR eGFR at the final observation − eGFR at the time of biopsy, NR no response, NS not significant
aAnalysis of variance between all FSGS vs MCNS, Student t test, or Fisher exact test